CDIO | Cardio Diagnostics Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.7256 - 0.8600
52 Week Range	0.1900 - 3.18
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,533,260
Average Volume	6,573,511
Shares Outstanding	40,439,810
Market Cap	29,529,149
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-01-14

Valuation
Profitability
Growth
Health
P/E Ratio	-2.43
Forward P/E Ratio	N/A
EPS	-0.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	7
Country	USA
Website	CDIO

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

CDIO's peers: ATNF, CYCN, DRMA, CELZ, ENSC, GOVX, HOTH, JAGX, KPRX, PHIO, QNRX, SABS, SMMT, SPRC, UNCY, OKYO, VRAX, IMMX, CNSP, EFTR, NAVB, SONN, ZURA, PYXS, CYTO, ELEV, ZVSA, VECT, AVRO, CDIOW, CMND

*Chart delayed

Analyzing fundamentals for CDIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see CDIO Fundamentals page.

Watching at CDIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CDIO Technicals page.